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Abstract
Background: Whilst multi-parametric magnetic resonance imaging (mp-MRI) has been a significant advance in the
diagnosis of prostate cancer, scanning all patients with elevated prostate specific antigen (PSA) levels is considered
too costly for widespread National Health Service (NHS) use, as the predictive value of PSA levels for significant
disease is poor. Despite the fact that novel blood and urine tests are available which may predict aggressive disease
better than PSA, they are not routinely employed due to a lack of clinical validity studies.
Furthermore approximately 40 % of mp-MRI studies are reported as indeterminate, which can lead to repeat
examinations or unnecessary biopsy with associated patient anxiety, discomfort, risk and additional costs.
Methods/Design: We aim to clinically validate a panel of minimally invasive promising blood and urine
biomarkers, to better select patients that will benefit from a multiparametric prostate MRI. We will then test
whether the performance of the mp-MRI can be improved by the addition of an advanced diffusion-weighted
MRI technique, which uses a biophysical model to characterise tissue microstructure called VERDICT; Vascular and
Extracellular Restricted Diffusion for Cytometry in Tumours.
INNOVATE is a prospective single centre cohort study in 365 patients. mp-MRI will act as the reference standard
for the biomarker panel. A clinical outcome based reference standard based on biopsy, mp-MRI and follow-up
will be used for VERDICT MRI.
Discussion: We expect the combined effect of biomarkers and VERDICT MRI will improve care by better
detecting aggressive prostate cancer early and make mp-MRI before biopsy economically viable for universal NHS
adoption.
Trial registration: INNOVATE is registered on ClinicalTrials.gov, with reference NCT02689271.
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Background
The management of prostate cancer poses difficult chal-
lenges, which is largely because we lack the necessary
tools to predict its presence, and discern between indo-
lent disease with a small chance of clinical manifestation
and aggressive tumours that are more likely to be lethal.
Since prostate cancer is a complex disease, it is unlikely
to be fully characterised with a single fluidic or diagnos-
tic imaging marker.
The standard and our institutional diagnostic pathways
After presenting with symptoms, or requesting screening
for prostate cancer, patients typically undergo a digital
rectal exam (DRE), combined with a prostate-specific
antigen (PSA) blood test.
PSA
PSA is a glycoprotein enzyme produced by normal prostate
epithelium and is routinely used as a serum biomarker for
prostate cancer, with raised levels typically provoking trans
rectal ultrasound (TRUS) biopsy. However, in addition to
prostate cancer, raised PSA levels are encountered in be-
nign prostatic hyperplasia (BPH), prostatitis and normal
prostate tissue, the PSA test has a fairly flat receiver oper-
ator characteristic curve, resulting in false positive and
negative results meaning it is relatively poor at predicting
or excluding significant prostate cancer [1, 2], which drives
the need for more specific circulating biomarkers in its
diagnosis. Circulating biomarkers in serum, plasma, urine,
and prostatic fluid have all been explored, but thus far re-
main invalidated to a defined standard in a cohort collected
under standardised conditions.
PCA3
PCA3 (prostate cancer antigen 3) is the only other rou-
tinely available biomarker, it is currently only available in
a private healthcare setting. The PCA3 test is carried
on urine out after DRE and detects a prostate specific
non-coding ribonucleic acid (RNA). The test has shown
clinical utility in diagnosing prostate cancer and can
discriminate tumour cells from benign [3–5]. When used
alongside magnetic resonance imaging (MRI) it shows a
correlation with tumour volume but PCA3 does not ap-
pear to correlate with other clinical parameters such as
stage and grade [6]. When used alongside MRI the accur-
acy of the PCA3 test can be improved, PCA3 score has
also been shown to correlate with suspicious MRI findings
and therefore could be used to select patients that require
an MRI, or because MRI outperforms the PCA3 it may
have greater utility in stratifying patients for active surveil-
lance or further biopsy [7–9].
MRI
In the last 5 years, the prostate cancer community has
undergone a pivotal change away from random transrec-
tal ultrasound (TRUS) sampling of the prostate and to-
wards image guided biopsy requiring multiparametric
(mp)-MRI, including T2 weighted (T2W), diffusion
weighted (DWI) and often dynamic contrast enhanced
(DCE) imaging.
In January 2014 the National Institute of Clinical Ex-
cellence (NICE) issued revised guidelines on the man-
agement of prostate cancer, which included the use of
mp-MRI in prostate cancer diagnostics [10]. In this
document, MRI was only recommended in those with a
negative TRUS and for staging where a change in
tumour (T) or nodal (N) staging would alter management.
The reason for this is likely to be due to the fact that
mp-MRI remains a less than perfect test. For example,
mp-MRI is relatively expensive, approximately 40 % of
patients have equivocal findings and performance is
modest for detection of small volume (<0.5 cc) tumour,
lower grade aggressive disease (secondary Gleason pattern
4) and for lesions within the transition zone. In addition,
the correlation of mp-MRI derived quantitative metrics
with Gleason grade is only moderate; meaning it lacks bio-
logical specificity. This means further repeat multipara-
metric MRI studies or unnecessary biopsies are often
necessitated, with associated patient discomfort, additional
risks and costs.
Our proposed new pathway
To address these limitations, we propose an approach
integrating promising fluidic markers together with ad-
vanced diffusion weighted MRI (VERDICT: Vascular,
Extracellular and Restricted DIffusion for Cytometry in
Tumours) within the diagnostic paradigm (Fig. 1).
Novel serum and urine biomarkers
The fluidic biomarkers we propose to investigate in our
study have been selected based on the number of studies,
patient reports and the ability of a marker to discriminate
tumour from benign or predict poor outcome (Additional
file 1). All markers can be tested in minimally invasive
samples e.g. whole blood, serum, plasma or urine. We en-
vision that these markers would help select patients most
likely to benefit from subsequent mp-MRI, thereby ratio-
nalising valuable NHS resources. Horizon scanning will
continue throughout the study to include any new and
promising markers.
VERDICT MRI
Most diffusion-weighted MRI studies have used the
technique in its simplest form by calculating the apparent
diffusion coefficient (ADC) to identify clinically significant
tumor foci more clearly [11, 12]. In general, ADC values
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are lower in prostate carcinoma compared with healthy
tissue but ADC values in both tissue types vary widely and
overlap substantially [12–14].
The recent VERDICT MRI technique [15] offers the
potential for explicit characterisation of tissue histology
non-invasively. A proof-of-concept study for assessment
of human prostate cancer [16] provided the basis for a
first-in-man study of clinical validity. In this study, we
imaged 8 patients with histologically confirmed periph-
eral zone cancer and demonstrated significant elevation
in tumour fractional intracellular and fractional vascular
volume, and a reduction in fractional extracellular extra-
vascular volume, in keeping with disease histology.
Since this work, the MRI protocol has been optimised,
using a computational optimisation framework [17] to
reduce the VERDICT scan time from 40 min to a more
clinically acceptable time of 15 min.
This is the world’s first clinical trial to investigate the
use of VERDICT MRI. We envision that application of
VERDICT MRI will improve the specificity of mp-MRI,
reduce the number of indeterminate examination results
and provide evaluation of the specific histological feature
changes associated with cancer.
Methods and analysis
Design
INNOVATE is a prospective cohort study with single
centre recruitment. The primary objective is to assess
whether supplementary VERDICT MRI improves the
diagnostic accuracy of mp-MRI for detection of significant
prostate cancer by a minimum of 10 %. The definitions of
significant cancer have been provided previously [18].
Participants undergo standard mp-MRI [19] ± biopsy,
together with studied index tests (fluidic markers and
VERDICT MRI). A 50 patient pilot phase held over 1 year
will provide histologically validated VERDICT MRI studies
in order to familiarise radiologists and ascend the learning
curve necessary for clinically interpreting VERDICT im-
ages. Initial evaluation of fluidic biomarker performance
for prediction of a negative mp-MRI result will be
conducted at the end of year 1 to derive thresholds for
prospective application. An evaluation phase held over
Fig. 1 Standard, our institutional and proposed new pathways for prostate cancer diagnosis
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2 years will prospectively test the added diagnostic ac-
curacy of VERDICT to standard mp-MRI. During the
evaluation phase, selected fluidic biomarker thresholds
will be applied to collected samples to prospectively
categorise patients into those expected to achieve
negative and positive (with a lesion) mp-MRI scores.
Patient population
Inclusion, exclusion and withdrawal criteria are provided
in Table 1 below.
Informed consent
Informed consent is a prerequisite and will be carried
out on the day of the trial interventions, following a
minimum 24-h period of consideration to participate in
the study.
Trial Interventions
The index test – VERDICT MRI
All studies will be performed on a 3 T MRI scanner
(Achieva, Philips, Amsterdam, NL). The total MRI
protocol including routine mp-MRI will be limited to a
maximum of 1-h scan time inclusive of 15 additional mi-
nutes allowed for VERDICT MRI. The mp-MRI protocol
will be standardized, as recommended as per the UK
consensus guidelines on prostate MRI [19], Table 2
below. 20 patients with tumours will undergo repeat
studies, with one group having immediate repeatability
(back to back scans) and another undergoing repeat
studies within a week to gauge the short term repeatabil-
ity of the parametric maps generated by VERDICT.
This is supplemented by an optimised VERDICT MRI
technique based on previously reported work [15], which
uses a Pulse-gradient spin-echo sequence and a 32 chan-
nel cardiac coil with b values of 90-3000 s/mm2 in 3
orthogonal directions. For b < 500 the number of averages
(NAV) = 6, for 500 < b < 1000 NAV= 12 and for b > 1000
NAV = 18 with voxel size = 1.3 × 1.3 × 5 mm, matrix
size = 176 × 176. The data is normalized with a b = 0
image for every echo time (TE) to avoid T2 dependence.
Scanning parameters for VERDICT MRI are provided in
Table 3.
The parametric maps generated from the VERDICT
scans produce measurements of the intracellular volume
fraction (fIC), cell radius (R), cellularity, extravascular
extracellular volume fraction (fEES) and vascular volume
fraction (fVasc). We also retain the fitting chi-squared
objective function (fobj), which is a sum of square differ-
ences adjusted to account for offset Rician noise bias, as in
[15, 16], to confirm successful fitting of the biophysical
VERDICT model has been or highlight regions where the
model is not appropriate. A typical example of such par-
ameter maps is provided in Fig. 2.
Reporting of mp-MRI and VERDICT MRI
MRI examination reports should record the suspicion of
cancer using an ordinal Likert scale (1 to 5): 1- tumour
highly unlikely, 2- tumour unlikely, 3- equivocal, 4- tumour
likely and 5- tumour highly likely. Strong evidence from
multiple institutions confirms mp-MRI is able to accurately
detect and localise ≥0.5 cc prostate cancer ≥Gleason 4
[19–21].
The first 50 patients VERDICT MRI studies will be
used to familiarise radiologists with VERDICT MRI de-
rived parameter maps, as they ascend the learning curve.
Radiologists will be allowed to review the VERDICT
MRI with access to biopsy results for correlation once
available. Potential conclusions drawn from VERDICT
datasets will not be included in clinical MRI reports as
at this stage we will not know the sensitivity or specifi-
city of VERDICT. These patients will not form part of
the main trial cohort.
A locked sequential read report for mp-MRI prior to
and following evaluation of VERDICT MRI will be per-
formed for the main trial cohort. mp-MRI results will be
made available to the clinical team as per standard prac-
tice. VERDICT MRI results will be collected using a case
report form but will not be revealed to the clinical care
team so as not to negatively influence patient care. A
radiologist will compare in vivo MR images and note
areas of abnormality as defined by the conventional mp-
MRI, and corresponding regions of interest (ROIs) on
the parametric VERDICT maps. In the case of prostatec-
tomy specimens, MR slices will be visually registered to
the pathological specimen. For biopsies targeted using
MRI, the lesion location can be ascertained from the op-
eration note/pathology report and in the case of positive
cores, specimens can be considered to be a successful
target.
Table 1 Inclusion, exclusion and withdrawal criteria
Patient Inclusion Criteria
1. Men referred to our center for prostate mp-MRI following biopsy
elsewhere
2. Biopsy naive men presenting to our institution with a clinical
suspicion of prostate cancer
Patient Exclusion Criteria
1. Men unable to have a MRI scan, or in whom artifact would reduce
quality of MRI
2. Men unable to given informed consent
3. Previous treatment (prostatectomy, radiotherapy, brachytherapy) of
prostate cancer
4. On-going hormonal treatment for prostate cancer
5. Previous biopsy within 6 months of scheduled mp-MRI
Withdrawal criteria
1. Images inadequate for analysis due to artifact or image acquisition
problems even after a repeat scan
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Table 2 MRI phasing details for standard multiparametric prostate MRI
Sequence Coil TR TE FA degrees WFS(pix) BW Hz/Px Fov mm Slice thickness
mm
Gap TSE
factor
Phasing direction FS ACQ matrix TFE shots TFE shot
interval (ms)
Total scan
duration
T2 TSE coronal Dual 6128 100 90 2.704 160.7 180 3 3 16 R > L No 300 x 290 05:55.4
T2 TSE axial Dual 5407 100 90 2.704 160.7 180 3 0 16 R > L No 300 x 290 05:13.6
T2 sag REF Dual 1579 100 90 1.999 217.3 240 5 5 20 A > P No 120 x 89 00:18.9
T1W TSE Dual 487 8 90 1.997 217.6 240 3 3 4 R > L No 184 x 184 03:06.8
DWI 0 150 500 1000 Dual 2753 80 90 40.353 10.8 220 5 0 A > P SPAIR 168 x 169 05:16.5
DWI b2000 Dual 2000 78 90 44.108 9.9 220 5 0 A > P SPIR 168 x 169 03:40.0
DCE 2 dyn mod SENSE Dual 5.8 2.8 90 1.766 246.1 180 3 0 38 (TFE) R > L SPAIR 140 x 177 49 280 00:28.9
DCE 20 dyn mod SENSE Dual 5.8 2.8 90 1.766 246.1 180 3 0 R > L SPAIR 140 x 162 45 280 04:14.1
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Quantitative measurements of vascular volume fraction,
extracellular extravascular volume fraction, intracellular
volume fraction, cell radius and cell density will be derived
from VERDICT for correlation against histological mea-
sures (see section 3.4.3).
Fluidic markers from blood and urine
Whole blood, serum, plasma and urine will be collected
from all patients in the study using existing standard oper-
ating procedures (SOPs) and assayed for diagnostic markers
(PCA3, AGR2 (Anterior gradient protein 2 homolog),
SPON2 (spondin 2), TMPRSS2 (Transmembrane protease
serine 2), EN2(Homeobox protein engrailed-2),
MSMB(Beta-microseminoprotein), GDF15(Growth dif-
ferentiation factor 15), SIK2 (Serine/threonine-protein
kinase) and CD10(cluster of differentiation 10)). Protein
markers in all matrices will be assayed on a MesoScale
discovery (MSD) platform and deoxyribonucleic acid
(DNA) will be extracted from whole blood to investi-
gate 22 prognostic single nucleotide polymorphisms
(SNPs) associated with aggressive disease. RNA for the
PCA3 and TMPRSS2 quantification from urine will be
extracted according to an SOP already developed in
our laboratory. qPCR for PCA3, TMPRSS2, 3 control
genes (TBP (TATA binding protein), SDH (succinate
dehydrogenase), RPLP2 (60S acidic ribosomal protein
P)) and PSA will be used in triplicate to quantify gene
expression. During the pilot phase we will continue to
horizon scan for new markers and have included scope
to add 2 further markers as evidence comes to light
and assays are developed e.g. GOLM1 (golgi membrane
protein 1), NAALADL2 (N-Acetylated Alpha-Linked
Acidic Dipeptidase-Like 2).
We will also extract exosomes from the serum and
plasma (when possible) of patients to derive molecular
tumour characteristics using fluorescence-lifetime im-
aging microscopy (FLIM) based measurements as well as
analysis of exosomal micro RNA (miRNA) that are
known to be associated with cell-to-cell communication
Fig. 2 VERDICT parameter maps. Images have been colour scaled. L to R, top to bottom: Original image b = 0 diffusion-weighted image. Prostate + lesion
showing original image with superimposed segmented lesion. Prostate segmentation + lesion segmentation. fIC = intracellular volume fraction. R = cell
radius. Cellularity map = calculated parametric map which shows the measured number of cells per voxel. fEES = Extracellular, extravascular
volume fraction, fVASC = vascular volume fraction. fobj = objective function. fIC, fEES and fVASC are all fractions, which add to 1. Cellularity is
number of cells per voxel, with units of cells/μm3. Objective function highlighting the ‘goodness of fit’ for the VERDICT model
Table 3 VERDICT MRI diffusion gradient parameters
b value s/mm2 Δ/δ ms TE ms |G| T/m
3000 19.7/38.8 80 0.0579
2000 13.2/32.3 67 0.0758
1500 24.7/43.8 90 0.0311
500 12.2/31.3 65 0.0415
90 4.7/23.8 50 0.0506
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and the development of cancer as well as immunosuppres-
sion leading to the development of further pre-metastatic
niche. Functional blood-derived miRNAs have been recog-
nised as potential robust biomarkers in the detection of
various types of cancer. The ability to screen for these
miRNAs and to perform FLIM of the epidermal growth
factor receptor (ErbB) family members will add important
prognostic and predictive information for diagnosis and
stratification of patients to treatment. Finally, we will sep-
arate peripheral blood mononuclear cells (PBMCs) from
whole blood of newly diagnosed prostate cancer patients
to perform immunophenotyping of immune cell popu-
lations with an ultimate goal to provide multi-modality
patient stratification.
Defining reference standards
Biomarker panel: mp-MRI result
Since it is envisaged that diagnostic biomarker thresh-
olds in the blood or urine will be able to predict a nega-
tive mp-MRI result, and act as a gatekeeper to effectively
rationalise its use, conventional mp-MRI result will form
the reference standard. Any lesion (Likert score 3 and
above) will be considered to be a positive result. VER-
DICT MRI will not be considered as part of the refer-
ence standard for fluidic markers as the utility of
VERDICT MRI remains unknown.
VERDICT MRI: histology/mpMRI based reference standard
A lesion based reference standard will be derived (Fig. 3).
mp-MRI has a 90-95 % negative predictive value for ex-
clusion of aggressive disease [22] and will therefore form
the reference for the index tests when mp-MRI is nega-
tive (Likert score 1-2/5). The positive predictive value of
mp-MRI is limited and reported between 60-70 %.
Therefore, where mp-MRI is positive (Likert score 3-5/5)
a prostatectomy or biopsy will be performed if clinically
appropriate. The prostatectomy or biopsy will then super-
sede the mp-MRI as the reference standard. Where a bi-
opsy or prostatectomy is not performed, patients will be
followed up with interval (6 months-1 year) mp-MRI as
part of standard clinical care. A progressive Likert score
(3/5 - > 4/5 or 5/5) or a progressive lesion (previously
scored 4-5) on repeat mp-MRI will be considered as
positive for the reference standard. A negative Likert
score (1-2/5) on the repeat mp-MRI will be considered
as negative for the reference standard. Lesions that remain
stable with Likert score 3/5 will be deemed indeterminate
and excluded from analysis unless biopsied. Based on pre-
vious internal audit, the total number of excluded patients
is predicted to be approximately 10 %.
Histopathological data processing and collection
The clinically most appropriate biopsy route for each pa-
tient will be used to obtain tissue, as informed by the
mp-MRI and discussed and documented at the prostate
Multi-disciplinary Team (MDT). Decision to biopsy or
perform prostatectomy will be based on mp-MRI (not
VERDICT MRI).
Tissue samples will be collected, fixed in formalin and
embedded in paraffin. Sections will be and stained with
hematoxylin and eosin (H&E) as per standard national
health service (NHS) protocols. Immunohistochemical
staining will also be performed for blood vessels and ca-
pillaries as per standard methods.
Histopathological assessment will be performed by
two blinded histopathologists independently and then in
consensus. Biopsy and whole block sections taken will
be analysed after conventional H&E staining to assess
tumor morphology including Gleason score, tumor vol-
ume/cancer core length, cell density, cell size distribu-
tion and percentage of epithelium/stroma. In addition
immunohistochemistry for vascular markers will be
performed for assessment of microvessel density.
To quantify the prostatic tissue components, automated
segmentation of the core biopsies shall be performed,
mapping blood vessels, lumen, epithelial cells and stroma
using software developed in house.
In addition, detailed histological correlation will be
sought for each of the specific imaging findings. A
database table will be constructed listing the imaging
observations and the histological findings listed in
Table 4, with histological scores provided for each main
observation.
Statistical considerations
Sample size calculation
A sample size of 280 subjects achieves 80 % power to
detect a difference of 0.1 between two diagnostic tests
whose specificities are 0.7 and 0.6. This calculation uses a
two-sided McNemar test with a significance level of 0.05.
The prevalence of patients with no cancer or insignificant
cancer (≤Gleason 3 + 3) is estimated at 0.6. The proportion
of discordant pairs is estimated at 0.2. Allowing for 10 % of
patients being excluded from the reference standard, a total
of 365 patients (50 to allow radiologist training, followed
by 315 patients for the main study) will be recruited. Based
on current practice at our institution, approximately 10
mp-MRI studies are performed per week in men that meet
the eligibility criteria. With a 50 % recruitment rate (note
our audit data from previous similar studies supports a re-
cruitment rate of 90 %), complete recruitment is expected
to take 73 weeks.
Outcome measures
All primary and secondary outcomes are presented in
Table 5 below.
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Table 4 Imaging parameters vs. histological correlates
VERDICT parameter Histological parameter
Intracellular volume fraction Cell coverage fraction per high power field
Vascular volume fraction Vascular coverage fraction per high power field
Extravascular extracellular volume fraction Glandular + stromal coverage fraction per high power field
Cell radius Average cell radius in a high power field
Cellularity Cell count per high power field
Fig. 3 Derivation of reference standard flow chart
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Data analysis and outcome assessment
Fluidic markers
The diagnostic accuracy of fluidic markers will also be
evaluated against the Likert score from the mpMRI, to
gauge whether they may be used as a sensitive gate-
keeper to reliably exclude patients in whom the mpMRI
result is likely to be negative (Likert 1/2). To do this, re-
sults of each fluidic marker will be compared against the
Likert score and a sensitivity and specificity will be ac-
quired allowing for Receiver operating curve (ROC) and
area under curve (AUC) analysis to subsequently be per-
formed. Cancer volume and Gleason grade will be corre-
lated with exosome levels, to judge whether they may
have any useful clinical application as biomarkers in the
future.
VERDICT MRI
Lesion based analysis will be performed to compare
specificity of mp-MRI with and without VERDICT MRI
(at a Likert threshold of 3/5 as positive) against the ref-
erence standard, to ascertain whether VERDICT has
any added diagnostic value. Correlation of VERDICT
derived maps and quantitative histological parameters
will also be assessed using correlation coefficients, and
Bland-Altman plots.
Finally, a full clinical demographic, fluidic marker,
qualitative and quantitative mp-MRI, and quantitative
VERDICT parameter database will be established for
future exploratory assessment and prediction of longer-
term patient outcome.
We believe the INNOVATE study will be important,
because it is one of the first clinical trials to bring to-
gether two important communities involved in prostate
cancer research in a single project, namely imaging and
fluidic biomarkers, who have traditionally worked in par-
allel. The findings of this study will also be particularly
interesting, as the results from clinical trials of potential
biomarkers are urgently needed and it also represents
the world’s first clinical trial involving VERDICT MRI.
Discussion
The INNOVATE study has some potential limitations.
Firstly, as an observational trial, we are unable to take
additional biopsies based on the VERDICT MRI result.
This is because it would be unethical to perform add-
itional biopsies at this stage of biomarker development,
as it would lead to unnecessary increased risk.
However, if VERDICT MRI is shown to be successful
in characterizing lesions within the prostate, additional
biopsies would be particularly desirable where lesions are
VERDICT positive but negative on conventional mpMRI,
to determine whether such discrepancies are due to
tumour.
Similarly, is also uncertain how many mp-MRIs will
have lesions that are subsequently biopsied, as diagnostic
and treatment decisions are made according to the
standard clinical pathway. In addition, since PSA is a
poor gatekeeper for MRI positive lesions, there will be a
considerable number of scans which are mp-MRI nega-
tive, which could be said to increase the cost and reduce
the efficiency of this trial, but will also allow us to better
understand the appearances of normal VERDICT signal.
As with any quantitative imaging study testing a new
sequence, the generalizability of data will be limited in the
first instance, and will only apply to our scanner. However,
if VERDICT is confirmed to be a repeatable and clinically
useful test for the diagnosis and characterization of
prostate cancer, our next step would be to conduct a
reproducibility study, using the VERDICT scan protocol
established on a different scanner. If the VERDICT se-
quence is confirmed to be acceptably reproducible, it
would need to be programmed and made available on
other scanners to confirm its usefulness as part of a multi-
center trial. In this way, the development of the VERDICT
sequence as a useful imaging biomarker should follow a
logical stepwise progression, according to biomarker road-
maps, such as those outlined in the consensus document
for use of diffusion-weighted MRI as a cancer biomarker
[23], or by Cancer Research UK [24].
This study is also limited to using a combined histo-
logical/imaging/follow-up reference standard. Such
Table 5 Primary and secondary outcome measures
Primary outcome
Radiological assessment with added VERDICT MRI improves the
diagnostic accuracy of mp-MRI for detection of significant prostate
cancer by a minimum of 10 %
Secondary outcomes
• A group of diagnostic fluidic markers measured on the MesoScale
discovery (MSD) platform and/or in DNA and RNA, can predict
patients with a negative mp-MRI result (i.e. 1-2/5 Likert score).
• The use of patient serum-derived exosomes as ‘liquid biopsies’ for
the identification of genomic and molecular aberrations that can
be used to better predict patients with aggressive or high volume
prostate cancer
• Technical validation of VERDICT:
○ VERDICT MRI is qualitatively and quantitatively repeatable
• Biological validation of VERDICT:
○ VERDICT cellularity measure correlates with histological cell
density
○ VERDICT intracellular volume fraction correlates with segmented
fractional histological intracellular component
○ VERDICT vascular volume fraction correlates with segmented
fractional histological vascular component
○ VERDICT extracellular extravascular volume fraction correlates
with fractional segmented histological glandular component +
stromal component
• Set-up of imaging/fluidic marker outcome linked database
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standards are commonly employed in radiological studies
when developing new techniques. Whilst tissue is usually
preferable, it would be unethical to sample patients with
no evident tumour at this stage of VERDICT develop-
ment. Where tissue is obtained, there is some debate as to
what forms the ideal histological reference standard.
Whilst whole mount prostatectomy provides the most
complete information with excellent spatial localization of
tumors, which can later be registered to MRI datasets,
prostatectomy cannot be used in all patients and therefore
suffers from spectrum bias, whereby more aggressive tu-
mors are selected [22]. Whilst template biopsy does not
experience this problem, registration of the biopsy co-
ordinates with the MRI is limited, and as a sampling tech-
nique is subject to sampling error [25], and may miss
smaller tumors <0.2 cc [26]. Despite these controversies,
both prostatectomy and template biopsy remain preferable
to TRUS biopsy, which remains the standard of care in
most centers but systematically misses 20 – 30 % of clinic-
ally significant cancers [27], particularly in the anterior
gland [28].
Conclusion
INNOVATE is a 365 patient cohort study being carried
out over 3 years, whereby we wish to validate a biomarker
panel to act as an effective gatekeeper to rationalize mp-
MRI for widespread NHS adoption. We aim to confirm
for the first time that VERDICT MRI is a repeatable tech-
nique and consider whether it can provide additional sen-
sitivity and specificity for the detection of prostate cancer.
If the parametric maps generated from VERDICT are
shown to correlate with Gleason grade better than current
quantitative multiparametric MRI measurands, VERDICT
MRI could prove useful in a range of circumstances in-
cluding the prevention or triggering prostate biopsy in
biopsy naïve patients, patients being monitored under
active surveillance and when assessing for disease recur-
rence following surgical, focal or radiotherapy.
Trial status
Investigators from UCLH designed the trial and UCLH
acts as the study sponsor. The UCLH Joint Research
Office maintains responsibility for monitoring of Good
Clinical Practice within the trial. A trial management
group for the study comprises specialists from the disci-
plines of Radiology, Radiography and Biomarker science.
Currently INNOVATE is open for recruitment in 1 Centre
in the United Kingdom. Recruitment commenced in April
2016 and is expected to finish in March 2019. INNOVATE
received UK Research Ethics Committee approval on 23rd
December 2015 by the NRES Committee London—Surrey
Borders with REC reference 15/LO/0692. INNOVATE is
published on clinicaltrials.gov [29].
Additional file
Additional file 1: A referenced list of the fluidic biomarkers to be tested
in the cohort. (DOCX 163 kb)
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